Rebecca Jane Fallis, MD | |
1235 Old York Rd Ste 220, Abington, PA 19001-3841 | |
(215) 481-6350 | |
(215) 481-4237 |
Full Name | Rebecca Jane Fallis |
---|---|
Gender | Female |
Speciality | Infectious Disease |
Experience | 10 Years |
Location | 1235 Old York Rd Ste 220, Abington, Pennsylvania |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033523691 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RI0200X | Internal Medicine - Infectious Disease | MD466413 (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Abington Memorial Hospital | Abington, PA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Abington Memorial Hospital | 3274437736 | 528 |
News Archive
Lean mass—the weight of an individual's bones, muscles and organs without body fat—appears to decline among patients with Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.
A study published in BioMed Central's open access journal, Arthritis Research & Therapy , found that increased waist circumference and body mass index (BMI) were associated with the risk of both knee and hip joint replacement.
Enzo Biochem Inc. announced today that favorable results of the Company's clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo's orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.
Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.
› Verified 8 days ago
Entity Name | Amh Medical Staff Service Fund |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1356384457 PECOS PAC ID: 9830003813 Enrollment ID: O20031114000011 |
News Archive
Lean mass—the weight of an individual's bones, muscles and organs without body fat—appears to decline among patients with Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.
A study published in BioMed Central's open access journal, Arthritis Research & Therapy , found that increased waist circumference and body mass index (BMI) were associated with the risk of both knee and hip joint replacement.
Enzo Biochem Inc. announced today that favorable results of the Company's clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo's orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.
Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.
› Verified 8 days ago
Entity Name | Abington Memorial Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1962554576 PECOS PAC ID: 3274437736 Enrollment ID: O20060223000079 |
News Archive
Lean mass—the weight of an individual's bones, muscles and organs without body fat—appears to decline among patients with Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.
A study published in BioMed Central's open access journal, Arthritis Research & Therapy , found that increased waist circumference and body mass index (BMI) were associated with the risk of both knee and hip joint replacement.
Enzo Biochem Inc. announced today that favorable results of the Company's clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo's orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.
Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Rebecca Jane Fallis, MD 2500 Maryland Rd Ste 400, Willow Grove, PA 19090-1225 Ph: (215) 481-4143 | Rebecca Jane Fallis, MD 1235 Old York Rd Ste 220, Abington, PA 19001-3841 Ph: (215) 481-6350 |
News Archive
Lean mass—the weight of an individual's bones, muscles and organs without body fat—appears to decline among patients with Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.
A study published in BioMed Central's open access journal, Arthritis Research & Therapy , found that increased waist circumference and body mass index (BMI) were associated with the risk of both knee and hip joint replacement.
Enzo Biochem Inc. announced today that favorable results of the Company's clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo's orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.
Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.
› Verified 8 days ago
Dr. Shaili Nepal, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2191 Fax: 215-481-3411 | |
Muhammad Arslan Asghar Cheema, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2222 Fax: 215-481-4361 | |
Margaret Mack, Infectious Disease Medicare: Medicare Enrolled Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Joseph Guererri Crocetti Jr., DO Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd, Ste 121, Abington, PA 19001 Phone: 215-517-1200 Fax: 215-517-1219 | |
Dr. Joseph Mcallister, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd, Ste 113, Abington, PA 19001 Phone: 215-517-1180 | |
William L. Ward, DO Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd, Suite 121, Abington, PA 19001 Phone: 215-517-1200 Fax: 215-517-1219 |